 vi. Patients with a systemic condition that, in the investigators opinion, might predispose to complications such as Down syndrome, autoimmune disease, pregnancy or nursing at the time of initial treatment, history of alcohol abuse, being immunocompromised, allergy to riboflavin or other study medications 